Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab

Journal of Medical Virology

Volumn 80, Issue 12, 2008, Pages 2069-2078

  Miyagawa, Masami ^a   Minami, Masahito ^a   Fujii, Kota ^a   Sendo, Rei ^a   Mori, Kojiro ^b   Shimizu, Daisuke ^a   Nakajima, Tomoaki ^a   Yasui, Kohichiroh ^a   Itoh, Yoshito ^a   Taniwaki, Masafumi ^a   Okanoue, Takeshi ^c   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

HBV reactivation; Mutation; Occult HBV infection; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE; VIRUS DNA;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONTROLLED STUDY; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; SEQUENCE ANALYSIS; SIDE EFFECT; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION; WILD TYPE;

AGED; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CLONING, MOLECULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MALE; MUTATION, MISSENSE; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSFECTION; VIRUS ACTIVATION; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 57349126260     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21311     Document Type: Article

References (63)

1. Alexopoulou A, Dourakis SP, Pandelidaki H, Archimandritis AJ, Karayiannis P. 2006a. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukemia treated with fludarabine. J Med Virol 78:1043-1046.
2. Alexopoulou A, Theodorou M, Dourakis SP, Karayiannis P, Sagkana E, Papanikolopoulos K, Archimandritis AJ. 2006b. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: Role of precore stop-codon and basic core promoter mutations. J Viral Hepat 13:591-596.
3. Aubourg A, d'Alteroche L, Senecal D, Gaudy C, Bacq Y. 2007. Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation. Gastroenterol Clin Biol 31:97-99.
4. Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH. 2007. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 38:83-86.
5. Besisik F, Karaca C, Akyuz F, Horosanli S, Onel D, Badur S, Sever MS, Danalioghi A, Demir K, Kayamakoglu S, Cakaloglu Y, Okten A. 2003. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. Hepatol 38:506-510.
6. Blum HE, Galun E, Liang TJ, Weizsäcker F, Wand JR. 1991. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 65:1836-1842.
7. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M. 2006. Characterization of HBV DNA+/HBsAg-blood donors in poland identified by triplex NAT. Hepatology 44:1666-1674.
8. Cariani E, Pelizzari AM, Rodella A, Gargiulo F, Imberti L, Manca N, Rossi G. 2007. Immune-mediated hepatitis-associated aplastic anemia by the emergence of a mutant hepatitis B virus undetectable by standard assays. J Hepatol 46:743-747.
9. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. 1995. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 345:1406-1407.
10. Chalandon Y, Negro F, Hebert D, Dietrich PY. 1999. Watchful monitoring for hepatitis B reactivation after intensive chemotherapy. Ann Oncol 10:483-484.
11. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. 2004. Occult hepatitis B virus infection in chronic liver disease: Full-length genome and analysis of mutant surface promoter. Gastroenterology 127:1356-1371.
12. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste EV, Salles G, Gaulard P, Reyes F, Gisselbrecht C. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242.
13. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Daillaire B, Varns C. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276.
14. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. 2004. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769-774.
15. Datta S, Banerjee A, Chandra PK, Chowdhury A, Chakravarty R. 2006. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers. J Med Virol 78:53-59.
16. Dervite I, Hober D, Morel P. 2001. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68.
17. Franceschini R, Cataldi A, Tenconi GL, Icardi G, Bruzzone BM. 2001. Reactivation of hepatitis B virus infection during cytotoxic chemotherapy. Am J Gastroenterol 96:606.
18. Gibb R, Nimmo GR, O'Loughlin P, Lowe P, Drummond D. 2007. Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection. J Med Virol 79:351-355.
19. Grethe S, Monazahian M, Böhme I, Thomssen R. 1998. Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 72:7692-7696.
20. Günter S, Li BC, Miska S, Krüger DH, Meisel H, Will H. 1995. Nobel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 69:5437-5444.
21. He C, Nomura F, Itoga S, Isobe K, Nakai T. 2001. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: A prospective study in 176 restaurant employees. J Gastroenterol Hepatol 16:1373-1377.
22. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayiannis P, Luo K. 2001. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative chinese carriers. Hepatology 34:1027-1034.
23. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. 1999. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30:1312-1317.
24. Huang X, Lu D, Ji G, Sun Y, Ma L, Chen Z, Zhang L, Huang J, Yu L. 2004. Hepatitis B virus (HBV) vaccine-induced escape mutants of HBS S gene among children from Qidong area, China. Virus Res 99:63-68.
25. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. 2006. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68.
26. Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Trapani RD, Ferraro D, Abbadessa V, Craxí A, Stefano RD. 2005. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 74:254-258.
27. Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. 2001. Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. J Med Virol 63:210-216.
28. Ishige K, Kawatani T, Suou T, Tajima F, Omura H, Idobe Y, Kawasaki H. 2001. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol 73:115-118.
29. Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A, Ohmura H, Ikuta Y, Idobe Y, Kawasaki H. 2001. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67:45-50.
30. Khattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo O, Zoulim F. 2005. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol 33:150-157.
31. Kreutz C. 2002. Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med 6:113-143.
32. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. 2005. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085-1089.
33. Lok AS, Liang RH, Chiu EK, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188.
34. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. 1999. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46:2925-2930.
35. Marusawa H, Imoto S, Ueda Y, Chiba T. 2001. Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. J Gastroenterol 36:633-636.
36. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, Trabaud MA, Chevallier P, Chevallier M, Zoulim F, Trepo C. 2007. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 79:1075-1081.
37. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM. 2007. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79:1464-1471.
38. Ng HJ, Lim LC. 2001. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report. Ann Hematol 80:549-552.
39. Niscola P, Principe MD, Maurillo L, Venditti A, Buccisano F, Piccioni D, Amadori S, Poeta GD. 2005. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19:1840-1841.
40. Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, Hopes E, Harrison TJ, Zuckerman AJ. 1995. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699-702.
41. Orlando R, Tosone G, Tiseo D, Piazza M, Portella G, Ciancia R, Martinelli V, Montante B, Rotoli B. 2006. Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients? Infection 34:282-284.
42. Özgönenel B, Moonka D, Savas,an S. 2006. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 81:302.
43. Pollicino T, Blloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. 2006. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823-837.
44. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. 2007. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:277-285.
45. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Büschenfelde KH, Neuhaus P, Gerken G. 1998. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263.
46. Radziwill G, Tucker W, Schaller H. 1990. Mutational analysis of the hepatitis B virus P gene product: Domain structure and RNase H activity. J Virol 64:613-620.
47. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. 1994. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
48. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. 1996. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108.
49. Rodriguez-Frias F, Buti M, Jardi R, Vargas V, Quer J, Cotrina M, Martell M, Esteban R, Guardia J. 1999. Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Liver 19:177-182.
50. Scarrecchia C, Cappelli A, Aiello P. 2005. HBV reactivation with fatal fulminanting hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HbsAb and HBcAb. J Infect Chemoter 11:189-191.
51. Sekine R, Taketazu F, Kuroki M, Takagi S, Imawari M, Kanazawa Y, Kawakami M. 2000. Fatal hepatic failure casued by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int J Hematol 71:256-258.
52. Senecal D, Pichon E, Dubois F, Delain M, Linassier C, Colombat P. 1999. Acute hepatitis B after autologus stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 24:1243-1244.
53. Sengupta S, Rehman S, Durgapal H, Acharya SK, Panda SK. 2007. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol 79:220-228.
54. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M. 2006. Anti-HBs-positive liver failure due to hepatitis B Virus Reactivation Induced by rituximab. Intern Med 45:721-724.
55. Skrabs C, Müller C, Agis H, Mannhalter C, Jäger U. 2002. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: A diagnostic and therapeutic challenge. Leukemia 16:1884-1886.
56. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N. 2004. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83:58-60.
57. Vitale F, Tramuto F, Orlando A, Vizzini G, Meli V, Cerame G, Mazzucco W, Virdone R, Palazzo U, Villafrate MR, Tagger A, Romano N. 2008. Can the serological status of "Anti-HBc Alone" be considered a sentinel marker for detection of "occult" HBV infection? J Med Virol 80:577-582.
58. Wands JR, Chura CM, Roll FJ, Maddrey WC. 1975. Serial studies of hepatitisassociated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68:105-112.
59. Westhoff TH, Jochimsen F, Schmittel A, Stöffler-Meilicke M, Schäfer JH, Zidek W, Gerlich WH, Thiel E. 2003. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102:1930.
60. Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda T, Nakamura M, Kusano K, Majima Y, Kuniyoshi T, Iijima M, Sugaya H, Hiraishi H. 2007. Fulminant Bhepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 48:431-433.
61. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. 2000. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307.
62. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ. 2004. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15:1661-1666.
63. Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ. 2004. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11:55-59.